Chordia Therapeutics (TYO:190A) has been selected to receive a 30 million yen grant for the fiscal year ending March 2026, stemming from a subcontract research and development agreement with Kyoto University, according to Tokyo bourse filing on Thursday.
This funding is for a non-clinical study on novel therapeutic agents for refractory tumours with RNA splicing mutations, under the Japan Agency for Medical Research and Development's (AMED) Research Project for Innovative Cancer Therapy Application.
While this grant will be recorded as non-operating income, it is not expected to impact Chordia's business forecast for the current fiscal year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.